Table 5.
Top 10 cited papers concerning the research of RCC immunotherapy.
| Title | Journals | First author | Year | Citations |
|---|---|---|---|---|
| Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer | New England Journal of Medicine | Topalian Suzanne L | 2012 | 8208 |
| Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer | New England Journal of Medicine | Brahmer Julie R | 2012 | 5217 |
| Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates | Journal of Clinical Oncology | Brahmer Julie R | 2010 | 2036 |
| Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy | Nature Reviews Cancer | Topalian Suzanne L | 2016 | 1332 |
| PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy | Molecular Cancer Therapeutics | Patel Sandip Pravin | 2015 | 1181 |
| Renal cell carcinoma | Lancet | Rini Brian I | 2009 | 1046 |
| Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma | Nature Medicine | Parsa Andrew T | 2007 | 970 |
| Cytokines in cancer pathogenesis and cancer therapy | Nature Reviews Cancer | Dranoff G | 2004 | 951 |
| Renal cell carcinoma | Nature Reviews Disease Primers | Hsieh James J | 2017 | 907 |
| The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy | Nature Reviews Cancer | Havel Jonathan J | 2019 | 901 |